Linzess\u00ae is the commercial brand name of Linaclotide, an orally administered guanylate cyclase-C (GC-C) agonist developed by Ironwood Pharmaceuticals and marketed by AstraZeneca in China. It acts locally on the intestinal epithelium to increase intestinal fluid secretion and accelerate transit, while also reducing visceral hypersensitivity, thereby improving constipation and abdominal symptoms.<\/p>\n\n\n\n
Main Indications<\/strong><\/p>\n\n\n\n In China, Linzess is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. In other regions, it is also indicated for chronic idiopathic constipation (CIC) in adults and functional constipation in eligible pediatric patients.<\/p>\n\n\n\n Common Side Effects<\/strong><\/p>\n\n\n\n The most frequently reported adverse reaction is diarrhea, which is usually mild to moderate. Other common side effects include abdominal pain, bloating, flatulence, nausea, and headache. Severe diarrhea may lead to dehydration, so the drug is contraindicated in children under 2 years of age.<\/p>\n\n\n\n China Launch Date<\/strong><\/p>\n\n\n\n Linzess (linaclotide capsules) received marketing approval from China’s National Medical Products Administration (NMPA) on January 15, 2019, becoming the first-in-class GC-C agonist approved in the country for IBS-C treatment. <\/p>\n\n\n\n Buy Linzess (Linaclotide Capsules)\u00a0online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.<\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n","protected":false},"excerpt":{"rendered":" Linzess\u00ae is the commercial brand name of Linaclotide, an orally administered guanylate cyclase-C (GC-C) agonist developed by Ironwood Pharmaceuticals and marketed by AstraZeneca in China. It acts locally on the intestinal epithelium to increase intestinal fluid secretion and accelerate transit, while also reducing visceral hypersensitivity, thereby improving constipation and abdominal symptoms. Main Indications In China, […]<\/p>\n","protected":false},"author":4,"featured_media":3094,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[101],"tags":[],"class_list":["post-3091","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug-news"],"blocksy_meta":[],"yoast_head":"\n